12-05-2025
Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Qiagen (QGEN)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Entrada Therapeutics Inc (TRDA – Research Report) and Qiagen (QGEN – Research Report).
Protect Your Portfolio Against Market Uncertainty
Entrada Therapeutics Inc (TRDA)
Roth MKM analyst Boobalan Pachaiyappan maintained a Buy rating on Entrada Therapeutics Inc yesterday and set a price target of $21.00. The company's shares closed last Friday at $8.38.
According to Pachaiyappan is a 1-star analyst with an average return of -6.3% and a 34.3% success rate. Pachaiyappan covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Gain Therapeutics, and Verona Pharma.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Entrada Therapeutics Inc with a $24.33 average price target, a 180.6% upside from current levels. In a report issued on May 8, TD Cowen also maintained a Buy rating on the stock.
Qiagen (QGEN)
In a report issued on May 8, Maja Pataki from Kepler Capital maintained a Hold rating on Qiagen, with a price target of EUR42.17. The company's shares closed last Friday at $41.86.
According to Pataki has 0 stars on 0-5 stars ranking scale with an average return of -13.7% and a 33.8% success rate. Pataki covers the Healthcare sector, focusing on stocks such as Tecan Group AG, Demant, and Alcon.
Qiagen has an analyst consensus of Moderate Buy, with a price target consensus of $49.29, representing a 14.5% upside. In a report issued on April 24, UBS also maintained a Hold rating on the stock.
